Erythropoiesis-stimulating agent hyporesponsiveness.

Area of Science:

• Nephrology
• Hematology

Background:

• 5-10% of chronic kidney disease (CKD) patients exhibit hyporesponsiveness to erythropoiesis-stimulating agents (ESA).
• ESA hyporesponsiveness significantly increases morbidity, mortality, and healthcare costs in CKD.
• Common causes include non-compliance, iron deficiency, and inflammation.

Purpose of the Study:

• To review the causes of ESA hyporesponsiveness in CKD patients.
• To evaluate the clinical evidence for proposed therapeutic interventions.
• To provide a practical algorithm for the investigation and management of ESA hyporesponsiveness.

Main Methods:

• Literature review of studies on ESA hyporesponsiveness in CKD.
• Analysis of evidence for various interventions targeting ESA resistance.
• Development of a diagnostic and management algorithm.

Main Results:

• Parenteral iron administration is key for managing iron deficiency and enhancing ESA efficacy.
• Several interventions show promise for inflammatory ESA hyporesponsiveness.
• Numerous other factors, including dialysis adequacy and nutrient deficiencies, can cause ESA resistance.

Conclusions:

• Effective management of ESA hyporesponsiveness requires addressing underlying causes like iron deficiency and inflammation.
• A systematic approach is necessary to optimize ESA therapy in CKD patients.
• Further research is needed to confirm the efficacy of various interventions.